home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

Immunotherapy and CAR-T(Chimeric antigen receptor) Cell Therapies: Overview & Current Status

 
  November 02, 2017  
     
 
CfPA-The Center for Professional Advancement, Online Live
December 11, 2017 at 11:00 a.m.–12:30 p.m. (ET)


Who Should Attend?
This online training is designed for professionals in the Pharmaceutical, Biotechnology, Medicine, Health Technologies, and Clinical Trials industries. Those working as Engineers, Scientists, Formulators, Managers, Technicians, Investors, Clinicians and Healthcare Professionals in departments such as Research and Development, Manufacturing, Regulatory, Pre-Clinical, Clinical will benefit greatly from this training.

Course Description
Immunotherapy has been heralded as the future of cancer treatment, providing another option to the traditional resection, radiation, and chemotherapy regimens. Harnessing the body’s natural ability to fight cancer, immunotherapies use the immune system to detect, prevent, and fight cancer. This course provides an overview of immunotherapy and CAR-T cell therapies, covering current classes of immunotherapies and targets as well as emerging research. 

The goal of this 90-minute, accredited training course is to provide attendees with a working knowledge of immune therapies for informed and effective decision making, project development and management, and patient care.

Can't Make this LIVE Webinar? 
Simply select the On Demand option when registering and we will send you the link to view the recorded version.

This course will be available On Demand: December 12, 2017
 
 
Organized by: CfPA-The Center for Professional Advancement
Invited Speakers:
Lindsey Ott, Ph.D., Director, Product Innovation, Likarda, LLC

Lindsey Ott is the Director of Product Innovation at Likarda, LLC, a biotechnology and cell therapy company in Kansas City. She obtained her Ph.D. and postdoctoral training from the University of Kansas in Bioengineering with a focus in Biomaterials and Tissue Engineering. Ms. Ott has published and patented work in the fields of tracheal tissue engineering, biomaterial fabrication, adult mesenchymal stem cells for musculoskeletal tissue engineering, and preclinical drug discovery using 3D hepatic organoids. Her current work focuses on developing cell-based assays for preclinical drug discovery, specifically in the areas of oncology, immunotherapies, and ADME-Tox.
 
Deadline for Abstracts: n/a
 
Registration: Please click here for registration information.
E-mail: jmorbit@cfpa.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.